达格列净治疗2型糖尿病合并慢性心力衰竭患者的临床研究进展  

Research progress in dapagliflozin for patients with type 2 diabetes and chronic heart failure

作　　者：武东 陈旭[2] 刘文光 马震[3] 汪小英 汪晓娟[1] WU Dong;CHEN Xu;LIU Wen-guang;MA Zhen;WANG Xiao-ying;WANG Xiao-juan(Department of Pharmacy,Fuyang People's Hospital,Fuyang Anhui 236000;Department of Clinical Pharmacy,Daqing Oilfield General Hospital,Daqing Heilongjiang 163000;Department of Cardiology,Fuyang People's Hospital,Fuyang Anhui 236000)

机构地区：[1]阜阳市人民医院药剂科,安徽阜阳236000 [2]大庆油田总医院临床药学科,黑龙江大庆163000 [3]阜阳市人民医院心血管内科,安徽阜阳236000

出　　处：《中南药学》2020年第8期1357-1360,共4页Central South Pharmacy

基　　金：阜阳市卫生健康委科研立项课题(No.FY2019-011)。

摘　　要：钠-葡萄糖协同转运蛋白-2抑制剂是一类新型降糖药物,目前广泛用于治疗2型糖尿病。达格列净作为中国首个批准用于临床的钠-葡萄糖协同转运蛋白-2抑制剂,在国内外已经完成多项注册临床研究,积累了大量临床应用的有效性和安全性数据。越来越多的心血管临床试验表明达格列净具有心血管保护作用,能降低患者因慢性心力衰竭导致的再住院风险和改善肾脏不良事件,其改善心肌病变的机制和降糖以外对心血管的保护作用是当前研究热点。本文拟综述达格列净治疗2型糖尿病合并慢性心力衰竭患者的临床疗效、安全性及改善心力衰竭可能的机制,旨在为其治疗2型糖尿病合并慢性心力衰竭提供更多的循证证据。Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a hypoglycemic agent for patients with type 2 diabetes mellitus.Dapagliflozin,the first SGLT-2i approved in China,has completed many registered clinical studies home and abroad,and accumulated data in effectiveness and safety.Increasing evidence suggests that dapagliflozin has multiple cardiovascular protective effects.The observed cardiovascular benefit is mainly attributed to lowering the rate of rehospitalization due to heart failure.Additionally,treatment with dapagliflozin is associated with a low rate of renal adverse events.The mechanism of improvement in cardiomyopathy and protection of the cardiovascular system besides hypoglycemia reducing the blood sugar by dapagliflozin are the focus of current research.This paper reviewed the clinical efficacy,safety and possible mechanism in improving heart failure of dapagliflozin in the treatment of type 2 diabetes and heart failure,and summarized possible evidence regarding the cardiovascular profile of dapagliflozin for patients with type 2 diabetes and heart failure.

关 键 词：达格列净 2型糖尿病 慢性心力衰竭 临床研究 

分 类 号：R587.1[医药卫生—内分泌]